Wave Life Sciences Ltd.WVENASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
5.53%
↓ 43% below average
Average (39q)
9.63%
Historical baseline
Range
High:77.39%
Low:-23.52%
CAGR
-6.0%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | 5.53% |
| Q2 2025 | 7.01% |
| Q1 2025 | -9.01% |
| Q4 2024 | 8.37% |
| Q3 2024 | 1.99% |
| Q2 2024 | 20.77% |
| Q1 2024 | -1.84% |
| Q4 2023 | 7.69% |
| Q3 2023 | -5.02% |
| Q2 2023 | 7.54% |
| Q1 2023 | -0.32% |
| Q4 2022 | 12.70% |
| Q3 2022 | -7.26% |
| Q2 2022 | 8.24% |
| Q1 2022 | 6.63% |
| Q4 2021 | -17.13% |
| Q3 2021 | -1.74% |
| Q2 2021 | -5.26% |
| Q1 2021 | 11.19% |
| Q4 2020 | 6.22% |
| Q3 2020 | -10.18% |
| Q2 2020 | -23.52% |
| Q1 2020 | -16.22% |
| Q4 2019 | 10.19% |
| Q3 2019 | 7.16% |
| Q2 2019 | 3.72% |
| Q1 2019 | 0.76% |
| Q4 2018 | 21.09% |
| Q3 2018 | 1.01% |
| Q2 2018 | 11.48% |
| Q1 2018 | 15.09% |
| Q4 2017 | 26.23% |
| Q3 2017 | 5.20% |
| Q2 2017 | 29.60% |
| Q1 2017 | 5.32% |
| Q4 2016 | 2.26% |
| Q3 2016 | 62.91% |
| Q2 2016 | 77.39% |
| Q1 2016 | 36.56% |
| Q4 2015 | 62.66% |